FIELD: biotechnology.
SUBSTANCE: following is presented are: the use of an anti-TIM-3 antibody molecule at a dose of 400 mg once every two weeks or 800 mg once every four weeks, for the treatment of cancer in a subject, a method of treating cancer in a subject, comprising administering to the subject an antibody molecule against TIM-3 and the use of a pharmaceutical composition containing an anti-TIM-3 antibody molecule.
EFFECT: invention can be used to treat or prevent oncological or infectious conditions.
54 cl, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| ANTI-HUMAN 4-1BB ANTIBODIES AND USE THEREOF | 2018 |
|
RU2725811C1 |
| ANTIBODIES AGAINST HUMAN 4-1BB AND THEIR USE | 2018 |
|
RU2777573C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| COMBINED TREATMENT METHODS USING ALK INHIBITORS | 2015 |
|
RU2718914C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
